Novonesis is a Denmark-based biosolutions company formed in 2024 through the combination of Novozymes and Chr. Hansen. The company develops, manufactures, and supplies industrial enzymes, microbial cultures, and other fermentation-derived ingredients for use across multiple end markets.
Novonesis’s technologies support applications in food and beverages (including cultures, probiotics, and processing enzymes), household and professional cleaning (detergent enzymes), bioenergy and biorefining, agriculture and animal nutrition (microbial and enzyme solutions), and health and nutrition. Its products are used to enhance process efficiency, support consistent product quality, and enable biological routes to production. The company operates global R&D, application development, and manufacturing facilities and collaborates with industrial and academic partners on biotechnology and fermentation-based processes.
The divestment is valued at €2.2 billion, with dsm-firmenich retaining a 20% stake. The deal includes a share buyback and a stable dividend policy. Completion expected by end of 2026.
A consortium progresses to phase two, optimizing CO2-to-food tech with renewed funding, aiming to create sustainable protein alternatives amid global hunger challenges.
